Michael J Duffy

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. ncbi request reprint Predictive markers in breast and other cancers: a review
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 51:494-503. 2005
  2. ncbi request reprint Mammaglobin a in breast cancer: existence of multiple molecular forms
    Neil A O'Brien
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 114:623-7. 2005
  3. doi request reprint Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer
    Fiona Lanigan
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
    Int J Cancer 124:2088-97. 2009
  4. ncbi request reprint Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer
    Jane Culleton
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 120:1087-92. 2007
  5. ncbi request reprint Use of a panel of novel genes for differentiating breast cancer from non-breast tissues
    Deirdre Foley
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Tumour Biol 28:312-7. 2007
  6. doi request reprint Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science and UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Clin Cancer Res 14:2681-9. 2008
  7. ncbi request reprint CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer
    Sallyann L O'Brien
    UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Int J Cancer 120:1434-43. 2007
  8. ncbi request reprint ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
  9. ncbi request reprint Expression of ADAM-9 mRNA and protein in human breast cancer
    Caroline O'Shea
    Conway Institute of Biomolecular and Biomedical Sciences, University College Dublin, Dublin, Ireland
    Int J Cancer 105:754-61. 2003
  10. ncbi request reprint Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, and Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Cancer Genomics Proteomics 4:121-34. 2007

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Predictive markers in breast and other cancers: a review
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 51:494-503. 2005
    ..Unpredictable efficacy and toxicity are hallmarks of most anticancer therapies. Predictive markers are factors that are associated with response or resistance to a particular therapy...
  2. ncbi request reprint Mammaglobin a in breast cancer: existence of multiple molecular forms
    Neil A O'Brien
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 114:623-7. 2005
    ..As expression of MGA is almost breast specific, it is a promising marker for breast cancer. Its most immediate use is likely to be in detecting micrometastases from breast cancer...
  3. doi request reprint Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer
    Fiona Lanigan
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
    Int J Cancer 124:2088-97. 2009
    ..We conclude that high levels of claudin-4 protein are associated with adverse outcome in breast cancer patients, including the subgroup of patients treated with adjuvant tamoxifen...
  4. ncbi request reprint Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer
    Jane Culleton
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 120:1087-92. 2007
    ..Since LPB was expressed relatively specifically in breast tissue and was significantly upregulated in breast carcinomas, it is a promising candidate biomarker for breast cancer...
  5. ncbi request reprint Use of a panel of novel genes for differentiating breast cancer from non-breast tissues
    Deirdre Foley
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Tumour Biol 28:312-7. 2007
    ..Genes such as MGA, B726P and SBEM that are expressed relatively exclusively in breast tissue are potential new markers for breast cancer...
  6. doi request reprint Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science and UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Clin Cancer Res 14:2681-9. 2008
    ..Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model...
  7. ncbi request reprint CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer
    Sallyann L O'Brien
    UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Int J Cancer 120:1434-43. 2007
    ..036) and overall survival (p=0.040). In conclusion, we identified CENP-F as a biomarker associated with poor outcome in breast cancer and showed several novel associations of biological significance...
  8. ncbi request reprint ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
    ..524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression...
  9. ncbi request reprint Expression of ADAM-9 mRNA and protein in human breast cancer
    Caroline O'Shea
    Conway Institute of Biomolecular and Biomedical Sciences, University College Dublin, Dublin, Ireland
    Int J Cancer 105:754-61. 2003
    ..05) and correlated positively with HER-2/neu protein levels (r = 0.313, p = 0.016). This is the first report to describe expression of any ADAM in a large number of human carcinomas...
  10. ncbi request reprint Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, and Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Cancer Genomics Proteomics 4:121-34. 2007
    ..Here, we review the role of DNA microarrays and tissue microarrays in the validation of biomarkers in breast cancer, with emphasis on their potential application to determine mode of personalised therapy in the future...
  11. ncbi request reprint Caspase 3 in breast cancer
    Norma O'Donovan
    Department of Medical Oncology, St Vincent s University Hospital, University College Dublin, Dublin 4, Ireland
    Clin Cancer Res 9:738-42. 2003
    ..One of the key mediators of apoptosis is the thiol protease caspase 3. In this investigation, caspase 3 mRNA and protein expression in breast cancer was examined...
  12. ncbi request reprint Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes
    Louise M Kelly
    Department of Surgery, Medical Oncology and Nuclear Medicine, St Vincent s University Hospital and Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
    Tumour Biol 26:213-6. 2005
    ..Our results do not suggest a role for BRMS1 in suppressing metastasis to local lymph nodes in patients with breast cancer...
  13. ncbi request reprint CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College, Dublin, and Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 12:6421-31. 2006
    ..We examined the potential prognostic and predictive role of CA IX in premenopausal breast cancer patients...
  14. pmc CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer
    Dhafir Al-azawi
    Department of Surgery, St, Vincent s University Hospital, Dublin, Ireland
    BMC Cancer 6:220. 2006
    ..Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer...
  15. ncbi request reprint High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 50:559-63. 2004
    ..CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease...
  16. ncbi request reprint Survivin: a promising tumor biomarker
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Cancer Lett 249:49-60. 2007
    ..Furthermore, assays for the measurement of survivin should be simplified, standardized and evaluated in external quality assurance schemes...
  17. doi request reprint Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
    ..The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha...
  18. doi request reprint The role of S100 genes in breast cancer progression
    Eadaoin McKiernan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Tumour Biol 32:441-50. 2011
    ..Based on our findings, we conclude that the different S100 genes play varying roles in breast cancer progression. Specific S100 genes are potential targets for the treatment of basal-type breast cancers...
  19. ncbi request reprint Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chem 48:1194-7. 2002
    ..The primary determinant of outcome in malignancy is the formation of distant metastases. Urokinase plasminogen activator (uPA) is a serine protease causally involved in invasion and metastasis...
  20. doi request reprint Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
    Aisling Pierce
    Education and Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Cancer Biol Ther 14:537-45. 2013
    ..e., whether HER2-positive, estrogen receptor (ER)-positive or triple-negative. Olaparib, in combination with a selective CDK1 inhibitor or a pan HER inhibitor, is a potential new approach for treating breast cancer...
  21. doi request reprint Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
    ..The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy...
  22. doi request reprint Intracellular and extracellular microRNAs in breast cancer
    Claire Corcoran
    School of Pharmacy and Pharmaceutical Sciences and Molecular Therapeutics for Cancer Ireland MTCI, Trinity College Dublin, Dublin, Ireland
    Clin Chem 57:18-32. 2011
    ..Toward this goal, it is essential to identify and understand the most relevant panels of biomarkers, some of which may also have relevance as therapeutic targets...
  23. doi request reprint Use of molecular markers for predicting therapy response in cancer patients
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Cancer Treat Rev 37:151-9. 2011
    ..The availability of predictive markers should increase drug efficacy and decrease toxicity, thus leading to a more personalized approach to cancer treatment...
  24. pmc Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
    Elton Rexhepaj
    UCD Conway Institute, University College Dublin, Belfield, Ireland
    BMC Cancer 10:639. 2010
    ..Here, we validate survivin CNR in a separate and extended cohort. Furthermore, we present new data suggesting that a low CNR may predict outcome in tamoxifen-treated patients...
  25. ncbi request reprint The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
    ..Finally, preclinical studies show that either inhibition of uPA catalytic activity or prevention of uPA binding to its receptor reduces tumor growth, angiogenesis and metastasis...
  26. ncbi request reprint Serum tumor markers in breast cancer: are they of clinical value?
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 52:345-51. 2006
    ..29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA...
  27. doi request reprint A personalized approach to cancer treatment: how biomarkers can help
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 54:1770-9. 2008
    ..quot; This practice is inefficient and frequently results in inappropriate therapy and treatment-related toxicity. In contrast, personalized treatment has the potential to increase efficacy and decrease toxicity...
  28. ncbi request reprint Evidence for the clinical use of tumour markers
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Ann Clin Biochem 41:370-7. 2004
    ..Although currently in widespread use, the value of prostate-specific antigen in screening for prostate cancer has yet to be validated in a large prospective randomized trial...
  29. doi request reprint CA 15-3: uses and limitation as a biomarker for breast cancer
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 411:1869-74. 2010
    ..The main limitation of CA 15-3 as a marker for breast cancer is that serum levels are rarely increased in patients with early or localized disease...
  30. doi request reprint Tumor markers in clinical practice: a review focusing on common solid cancers
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Med Princ Pract 22:4-11. 2013
    ..Although widely used, the value of prostate-specific antigen screening in reducing mortality from prostate cancer is unclear...
  31. doi request reprint Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin and UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Int J Cancer 128:3-11. 2011
    ....
  32. ncbi request reprint The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009
    ..Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma...
  33. ncbi request reprint Mammaglobin a: a promising marker for breast cancer
    Neil O'Brien
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chem 48:1362-4. 2002
  34. ncbi request reprint The ADAMs family of proteins: from basic studies to potential clinical applications
    Michael J Duffy
    Dept of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Thromb Haemost 89:622-31. 2003
    ..Altered expression of certain ADAMs has been associated with a number of diseases including asthma, arthritis, Alzheimer's disease, atherosclerosis and cancer...
  35. ncbi request reprint Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Biochem Soc Trans 30:207-10. 2002
    ..e. in both a randomized prospective trial and a pooled analysis. Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients...
  36. ncbi request reprint Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  37. ncbi request reprint Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response
    Donal J Brennan
    Conway Institute of Biomolecular and Biomedical Research, Department of Pharmacology, Centre for Molecular Medicine, University College Dublin, Dublin 4, Ireland
    Expert Opin Biol Ther 5:1069-83. 2005
    ..The most recent data supporting the integration of various publicly available data sets is also reviewed in detail...
  38. ncbi request reprint Breast cancer proteomics: clinical perspectives
    Thomas Y K Lau
    UCD Conway Institute, UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland
    Expert Opin Biol Ther 7:209-19. 2007
    ..It aims to analyse the complex circuitry of the breast cancer proteome. Here, the authors review how breast cancer proteomics has progressed so far, with emphasis on its potential application to clinically relevant scenarios...
  39. ncbi request reprint Tumor markers in breast cancer- European Group on Tumor Markers recommendations
    Rafael Molina
    Laboratory of Biochemistry, Hospital Clinic, Medical School, Barcelona, Spain
    Tumour Biol 26:281-93. 2005
    ....
  40. ncbi request reprint Tumor-associated alterations in caspase-14 expression in epithelial malignancies
    Maryla Krajewska
    The Burnham Institute, La Jolla, California, USA
    Clin Cancer Res 11:5462-71. 2005
    ..We investigated caspase-14 expression in several types of human epithelial malignancy by immunohistochemistry, correlating results with stage, histologic grade, and patient survival...
  41. doi request reprint Bcl-B expression in human epithelial and nonepithelial malignancies
    Maryla Krajewska
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Clin Cancer Res 14:3011-21. 2008
    ..Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported...
  42. ncbi request reprint Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients
    Alexei Y Savinov
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 66:2716-24. 2006
    ....